Indoco Remedies bags USFDA nod for Lacosamide Injection
Lacosamide injection is indicated for the prevention and control of seizures.
Mumbai: Indoco Remedies Ltd. today announced that the United States Food & Drug Administration (USFDA) has approved the ANDA Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL) single-dose vials.
The generic Lacosamide Injection USP of lndoco Remedies is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vimpat Injection of UCB, Inc.
Lacosamide injection is indicated for the prevention and control of seizures. It is an anticonvulsant / antiepileptic drug.
Commenting on the development, Ms. Aditi Kare Panandikar, Managing Director-lndoco Remedies said, "Lacosamide Injection of lndoco is the first generic version of Vimpat Injection of UCB Inc., approved in the United States. The ANDA approval and immediate launch of the product in the US market, echoes our commitment and consistent efforts to meet the unmet needs of the patients with quality and affordable healthcare."
According to available IQVIA, sales data for Vimpat Injection is approx. USD 43.8 million, growing at 25%.
Read also: Indoco Remedies receives USFDA nod for Lacosamide Tablets
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.